Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Raw Materials (2023 - 2025)

Catalyst Pharmaceuticals' Raw Materials history spans 3 years, with the latest figure at $17.1 million for Q4 2025.

  • For Q4 2025, Raw Materials rose 162.92% year-over-year to $17.1 million; the TTM value through Dec 2025 reached $17.1 million, up 162.92%, while the annual FY2025 figure was $17.1 million, 162.92% up from the prior year.
  • Raw Materials reached $17.1 million in Q4 2025 per CPRX's latest filing, up from $12.1 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $17.1 million in Q4 2025 to a low of $1.9 million in Q4 2023.
  • Average Raw Materials over 3 years is $7.9 million, with a median of $6.7 million recorded in 2024.
  • Peak YoY movement for Raw Materials: soared 241.26% in 2024, then fell 7.34% in 2025.
  • A 3-year view of Raw Materials shows it stood at $1.9 million in 2023, then skyrocketed by 241.26% to $6.5 million in 2024, then soared by 162.92% to $17.1 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Raw Materials are $17.1 million (Q4 2025), $12.1 million (Q3 2025), and $5.2 million (Q2 2025).